p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness

M. Yokoyama, Y. Yamanaka, H. Friess, M. Buchler, Murray Korc

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Immunohistochemical analysis of the p53 tumor suppressor gene was perfomted in 69 human pancreatic ductal adenocarcinomas, using a highly specific anti-p53 antibody. Nuclear immunoreactivity was found in 40 tumors, yielding an overall frequency of 58%. Immunoblotting confirmed that nuclear immunoreactivity was associated with increased p53 protein levels. p53 mRNA levels were increased in 9 of 9 tested cancers, without evidence for gene amplification. Analysis of the immunostaining data by chi-square and log-ran indicated that the presence of nuclear immunoreacrtivity correlated with a more advanced clinical stage, and a statistically significant decrease in the post-operativesuwival period. In 12 cancers, metastatic tissue samples were also available for p53 analysis. Nuclear p53 immunostaining in the primary atmon was not always associated with p53 immunoreacfivity in the metastatic samples, and metastases occurred in the absence of nuclear p53 immunorenctivity in the piimaly lesion. These findings suggest that increased p53 protein levels in human pancreatic cancer may be due not only to p53 mutations which attenuate the degrandation of the protein but also to an incrense in p53 mRNA levels leading to increased p53 synthesis, and that p53 nuclear immunoreactivity in these cancers implies enhanced tumor aggressiveness but is not essential for the development of metastases.

Original languageEnglish (US)
Pages (from-to)2477-2483
Number of pages7
JournalAnticancer Research
Volume14
Issue number6 B
StatePublished - 1994
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Neoplasms
Neoplasm Metastasis
Messenger RNA
Proteins
Gene Amplification
Tumor Suppressor Genes
Immunoblotting
Anti-Idiotypic Antibodies
Adenocarcinoma
Mutation

Keywords

  • Human pancreatic cancer
  • p53
  • Post-operative survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yokoyama, M., Yamanaka, Y., Friess, H., Buchler, M., & Korc, M. (1994). p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Research, 14(6 B), 2477-2483.

p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. / Yokoyama, M.; Yamanaka, Y.; Friess, H.; Buchler, M.; Korc, Murray.

In: Anticancer Research, Vol. 14, No. 6 B, 1994, p. 2477-2483.

Research output: Contribution to journalArticle

Yokoyama, M, Yamanaka, Y, Friess, H, Buchler, M & Korc, M 1994, 'p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness', Anticancer Research, vol. 14, no. 6 B, pp. 2477-2483.
Yokoyama M, Yamanaka Y, Friess H, Buchler M, Korc M. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Research. 1994;14(6 B):2477-2483.
Yokoyama, M. ; Yamanaka, Y. ; Friess, H. ; Buchler, M. ; Korc, Murray. / p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. In: Anticancer Research. 1994 ; Vol. 14, No. 6 B. pp. 2477-2483.
@article{4a3f25ec25a34c7ea3c64ccd4a60c8a3,
title = "p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness",
abstract = "Immunohistochemical analysis of the p53 tumor suppressor gene was perfomted in 69 human pancreatic ductal adenocarcinomas, using a highly specific anti-p53 antibody. Nuclear immunoreactivity was found in 40 tumors, yielding an overall frequency of 58{\%}. Immunoblotting confirmed that nuclear immunoreactivity was associated with increased p53 protein levels. p53 mRNA levels were increased in 9 of 9 tested cancers, without evidence for gene amplification. Analysis of the immunostaining data by chi-square and log-ran indicated that the presence of nuclear immunoreacrtivity correlated with a more advanced clinical stage, and a statistically significant decrease in the post-operativesuwival period. In 12 cancers, metastatic tissue samples were also available for p53 analysis. Nuclear p53 immunostaining in the primary atmon was not always associated with p53 immunoreacfivity in the metastatic samples, and metastases occurred in the absence of nuclear p53 immunorenctivity in the piimaly lesion. These findings suggest that increased p53 protein levels in human pancreatic cancer may be due not only to p53 mutations which attenuate the degrandation of the protein but also to an incrense in p53 mRNA levels leading to increased p53 synthesis, and that p53 nuclear immunoreactivity in these cancers implies enhanced tumor aggressiveness but is not essential for the development of metastases.",
keywords = "Human pancreatic cancer, p53, Post-operative survival",
author = "M. Yokoyama and Y. Yamanaka and H. Friess and M. Buchler and Murray Korc",
year = "1994",
language = "English (US)",
volume = "14",
pages = "2477--2483",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness

AU - Yokoyama, M.

AU - Yamanaka, Y.

AU - Friess, H.

AU - Buchler, M.

AU - Korc, Murray

PY - 1994

Y1 - 1994

N2 - Immunohistochemical analysis of the p53 tumor suppressor gene was perfomted in 69 human pancreatic ductal adenocarcinomas, using a highly specific anti-p53 antibody. Nuclear immunoreactivity was found in 40 tumors, yielding an overall frequency of 58%. Immunoblotting confirmed that nuclear immunoreactivity was associated with increased p53 protein levels. p53 mRNA levels were increased in 9 of 9 tested cancers, without evidence for gene amplification. Analysis of the immunostaining data by chi-square and log-ran indicated that the presence of nuclear immunoreacrtivity correlated with a more advanced clinical stage, and a statistically significant decrease in the post-operativesuwival period. In 12 cancers, metastatic tissue samples were also available for p53 analysis. Nuclear p53 immunostaining in the primary atmon was not always associated with p53 immunoreacfivity in the metastatic samples, and metastases occurred in the absence of nuclear p53 immunorenctivity in the piimaly lesion. These findings suggest that increased p53 protein levels in human pancreatic cancer may be due not only to p53 mutations which attenuate the degrandation of the protein but also to an incrense in p53 mRNA levels leading to increased p53 synthesis, and that p53 nuclear immunoreactivity in these cancers implies enhanced tumor aggressiveness but is not essential for the development of metastases.

AB - Immunohistochemical analysis of the p53 tumor suppressor gene was perfomted in 69 human pancreatic ductal adenocarcinomas, using a highly specific anti-p53 antibody. Nuclear immunoreactivity was found in 40 tumors, yielding an overall frequency of 58%. Immunoblotting confirmed that nuclear immunoreactivity was associated with increased p53 protein levels. p53 mRNA levels were increased in 9 of 9 tested cancers, without evidence for gene amplification. Analysis of the immunostaining data by chi-square and log-ran indicated that the presence of nuclear immunoreacrtivity correlated with a more advanced clinical stage, and a statistically significant decrease in the post-operativesuwival period. In 12 cancers, metastatic tissue samples were also available for p53 analysis. Nuclear p53 immunostaining in the primary atmon was not always associated with p53 immunoreacfivity in the metastatic samples, and metastases occurred in the absence of nuclear p53 immunorenctivity in the piimaly lesion. These findings suggest that increased p53 protein levels in human pancreatic cancer may be due not only to p53 mutations which attenuate the degrandation of the protein but also to an incrense in p53 mRNA levels leading to increased p53 synthesis, and that p53 nuclear immunoreactivity in these cancers implies enhanced tumor aggressiveness but is not essential for the development of metastases.

KW - Human pancreatic cancer

KW - p53

KW - Post-operative survival

UR - http://www.scopus.com/inward/record.url?scp=0028670932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028670932&partnerID=8YFLogxK

M3 - Article

C2 - 7872670

AN - SCOPUS:0028670932

VL - 14

SP - 2477

EP - 2483

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -